EMA Grants Waivers To Test StemEx From Gamida Cell-Teva JV
StemEx is being developed by a joint venture equally owned and operated by Gamida Cell and Teva Pharmaceuticals. Moreover, a company has to submit to the PDCO a
The US Food and Drug Administration (FDA) has approved an expanded indication for Eli Lilly and Company’s Jaypirca (pirtobrutinib) as a first-line treatment for adults with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a 17p deletion.